CYP2B6 Polymorphisms in Ketamine

Completed · Not applicable

Conditions studied: Healthy Volunteers

In brief

This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes ketamine.

Key facts

Study ID

NCT01988922

Run by

Washington University School of Medicine

People needed

30

Starts

2013-11-01

Expected to finish

2017-05-01

Last updated by the study team

2018-05-18

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18-50 yr old
• CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype (see table) (Note: subjects of other rare genotype but with one or more 516G>T, 785A>G, 983T>C or 1459C>T polymorphism may be enrolled at PI's discretion)
• Good general health with no remarkable medical conditions
• BMI <33
• Provided informed consent

You may not qualify if…

• Known history of liver or kidney disease
• Use of prescription or non prescription medications, herbals, foods or chemicals known to be metabolized by or affecting CYP2B6
• Females who are pregnant or nursing
• Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)
• Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.